Severe Hepatic Injury Caused by Imatinib Mesylate Administered for the Treatment of Chronic Myeloid Leukemia and the Efficacy of Prednisolone for its Management

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International journal of hematology

• Publication date

  2005-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1532/IJH97.05034PMID 16298828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Severe Hepatitis and Complete Molecular Response Caused by Imatinib Mesylate: Possible Association of Its Serum Concentration with Clinical Outcomes

  2004cited by this paper
• Fatal hepatic necrosis following imatinib mesylate therapy.

  2003cited by this paper
• Histological features of acute hepatitis after imatinib mesylate treatment

  2003cited by this paper
• Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.

  2003cited by this paper
• Adverse events after imatinib mesylate therapy.

  2002cited by this paper
• STI571: a paradigm of new agents for cancer therapeutics.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Adverse events after imatinib mesylate therapy.

  2002cited by this paper
• Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

  2002cited by this paper
• Chronic myeloid leukemia: current treatment options.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.

  2001cited by this paper
• Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway.

  1996cited by this paper
• Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor.

  1992cited by this paper

• The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review

  2023cites this paper
• Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians.

  2020cites this paper
• Novel Score-based Decision Approach in Chronic Myeloid Leukemia Patients After Acute Toxic Imatinib-induced Liver Injury

  2019cites this paper
• Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis

  2018cites this paper
• Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor

  2016influential citation
• Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review

  2015influential citation
• Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity

  2013cites this paper
• Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

  2011cites this paper
• Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone

  2011cites this paper
• Histopathological study of the hepatic and renal toxicity associated with the co-administration of imatinib and acetaminophen in a preclinical mouse model.

  2010cites this paper
• Gastrointestinal toxicities of novel agents in cancer therapy.

  2009cites this paper
• Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia.

  2009cites this paper
• Dasatinib-induced acute hepatitis

  2008cites this paper
• Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

  2008cites this paper
• Élaboration d'outils pour informer les professionnels de santé de ville sur la prise en charge des effets indésirables des anticancéreux par voie orale

  2008cites this paper
• Hepatitis tóxica por imatinib: descripción de dos casos y revisión de la literatura médica

  2007cites this paper
• Successful Imatinib Treatment of Cardiac Involvement of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia Followed by Severe Hepatotoxicity

  2007influential citation
• [Imatinib-induced toxic hepatitis: description of two cases and review of the literature].

  2007cites this paper
• Management of imatinib mesilate (IM)-related hepatic injury by adjusting the dose of the drug in a patient with chronic myelogenous leukemia (CML): A case report

  2007cites this paper
• Cancer chemotherapy I: hepatocellular injury.

  2007cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2006cites this paper